ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
Key Highlights
- ➤Cash $44.1 million expected to fund operations through 2027
- ➤PRECISE-AD topline data remains scheduled for first quarter 2027
- ➤PMN310 interim data showed no ARIA-E and 4.4% ARIA-H in 136 patients
- ➤Q3 net loss $8.2 million, or $(0.89) per share
- ➤Ivana Rubino appointed Chief Commercial Officer effective October 5, 2026
Expert Statements
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
“The third quarter of 2026 has been productive for ProMIS, following encouraging interim data from our Phase 1b PRECISE-AD trial in Alzheimer’s disease (AD).”
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
“Based on data generated to date, we continue to believe PMN310 offers a differentiated approach by selectively targeting the most toxic and destructive form of amyloid-beta, the oligomers.”
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
“Despite claims of precision targeting, other antibodies have consistently shown binding to multiple forms of amyloid-beta, including plaque, resulting in a significant incidence of ARIA.”
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
“If PMN310 is able to shift the benefit-risk profile as compared to the existing standard of care, with ARIA rates similar to placebo and, at a minimum, similar efficacy, we believe PMN310 could be positioned to take a leadership position in the treatment not only of early AD patients, but potentially of asymptomatic (preclinical) AD patients.”
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
“With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures.”
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
“PMN310’s Fast Track Designation allows for more frequent engagement with the United States Food and Drug Administration (FDA), and we plan to request a meeting with the agency next year, after the full data set has been analyzed.”
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
“In parallel, we are advancing development of a subcutaneous formulation of PMN310 and preparing for a registrational study that, subject to FDA feedback, we anticipate initiating toward the end of 2027.”
* PRECISE-AD Phase 1b clinical trial in Alzheimer’s patients remains on track for unblinded 12-month topline data in the first quarter of 2027, including full safety, biomarker and cognitive outcomes data * PMN310 binds selectively to toxic amyloid-beta oligomers, and its IgG1 backbone is designed to promote clearance of toxic oligomers * Ivana Rubino, Ph.D., a seasoned Alzheimer’s commercial leader, appointed Chief Commercial Officer * Cash of $44.1 million as of September 30, 2026, expected to fund operations through 2027, beyond the anticipated PRECISE-AD topline data readout Cambridge, Massachusetts, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2026, and provided a corporate update.
Get started
Create a free account to read the full story.